下载 Bayesian Designs for Phase I–II Clinical Trials (Chapman & Hall/CRC Biostatistics Series) MOBI

书 Bayesian Designs for Phase I–II Clinical Trials (Chapman & Hall/CRC Biostatistics Series) 位于网站上免费访问和优质，所以在任何移动设备上阅读它是非常方便和舒适。 去下载 Bayesian Designs for Phase I–II Clinical Trials (Chapman & Hall/CRC Biostatistics Series) 网站上的MOBI不需要注册或付款即可访问该文件。 检查文件是否有错误和病毒，因此请确保我们网站的可下载资料的质量。 快速下载速度将有助于节省时间并尽快投入阅读。 您可以通过下载文件或在网站上在线阅读移动设备上的图书。 如果您在设备的内存中下载电子书，即使在线下时也可以随时阅读。 还要注意目录中的其他书籍，以便收集最适合您的口味和偏好的小型电子出版物，并随时随地阅读。 Reliably optimizing a new treatment in humans is a critical first step in clinical evaluation since choosing a suboptimal dose or schedule may lead to failure in later trials. At the same time, if promising preclinical results do not translate into a real treatment advance, it is important to determine this quickly and terminate the clinical evaluation process to avoid wasting resources. Bayesian Designs for Phase I–II Clinical Trials describes how phase I–II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory clinical trials. It illustrates many of the severe drawbacks with conventional methods used for early-phase clinical trials and presents numerous Bayesian designs for human clinical trials of new experimental treatment regimes. The first two chapters minimize the technical language to make them accessible to non-statisticians. These chapters discuss the severe drawbacks of the conventional paradigm used for early-phase clinical trials and explain the phase I–II paradigm for optimizing dose, or more general treatment regimes, based on both efficacy and toxicity. The remainder of the book covers a wide variety of clinical trial methodologies, including designs to optimize the dose pair of a two-drug combination, jointly optimize dose and schedule, identify optimal personalized doses, optimize novel molecularly targeted agents, and choose doses in two treatment cycles. Written by research leaders from the University of Texas MD Anderson Cancer Center, this book shows how Bayesian designs for early-phase clinical trials can explore, refine, and optimize new experimental treatments. It emphasizes the importance of basing decisions on both efficacy and toxicity. 我们提供阅读或下载 Bayesian Designs for Phase I–II Clinical Trials (Chapman & Hall/CRC Biostatistics Series) 我们网站上的MOBI是完全免费的，没有注册。 本书已完整并经过病毒测试，因此，通过从我们这里下载此电子版，您可以完全享受阅读，而不会对您用于阅读的移动设备造成任何威胁。 下载不需要付费，因为本书是供用户阅读和阅读的。 如果你喜欢这本书 Bayesian Designs for Phase I–II Clinical Trials (Chapman & Hall/CRC Biostatistics Series) ，注意以同一类型编写的其他出版物。 该目录提供了丰富的出版物选择，因此您不难建立一个优秀的图书馆。